Independent research on the U.S. markets, Baptista Research

Baptista Research

Independent research on the U.S. markets

Baptista Research is an independent financial research house focused on the U.S. markets. We provide equity research as well as credit research reports on the top-listed U.S. companies with most of our focus on technology, consumer goods and services, automobiles, industrials, oil and gas, pharma, and healthcare. Our research has served more than 3000 institutional investors including mutual funds, hedge funds, banks, family offices, and various buy-side firms. We operate a research subscription service where institutions, as well as retail investors, can have priority access to all our research. We also have a wide distribution of our research reports across some of the top global financial platforms. Apart from equity research and credit research, we also provide advisory services with respect to mergers & acquisitions (M&A), private equity/ venture capital fundraising, valuation reports, and investment management services for corporates.
Baptista Research is owned and managed by Ishan Majumdar, an ex-Venture Capitalist/ Investment Banker, a Chartered Accountant, and a Masters’ degree holder in Management from HEC Paris. Ishan has nearly a decade of experience in Mergers and Acquisitions, Leveraged Buyouts (LBOs), Venture Capital Investing, Corporate Strategy, and Valuation in front-office roles at the likes of BNP Paribas CIB, Credit Agricole CIB, Groupe Danone, and TIW Private Equity. He has worked on and closed multiple acquisition deals, leveraged buyouts, and start-up investment transactions.

Equity Bottom-Up

<ul><li>ResMed's financial performance in the second quarter of fiscal year 2026 offers insights into its operational strengths and market challenges.</li><li>The company reported an 11% increase in headline revenue, or 9% growth on a constant currency basis, showcasing solid market performance across its global segments.</li><li>The revenue of $1.42 billion is buoyed by robust growth in device and mask sales, particularly in the U.S., Canada, and Latin America, where sales grew by 11%.</li></ul>

ResMed's financial performance in the second quarter of fiscal year 2026 offers insights into its operational strengths and market challenges.The company reported an 11% increase in headline revenue, or 9% growth on a constant currency basis, showcasing solid market performance across its global segments.The revenue of $1.42 billion is buoyed by robust growth in device and mask sales, particularly in the U.S., Canada, and Latin America, where sales grew by 11%.

ResMed’s Multi-Vector Growth Story: GLP-1 Tailwinds, Primary Care Expansion, and Digital Health!

Derivatives and Quantitative Strategist

Gaudenz Schneider

<ul>
<li>
Context: The <a href="https://www.smartkarma.com/entities/fisher-paykel-healthcare-cor" target="_blank" data-smartkarma-citation="entities:24208:1" rel="noopener">Fisher &amp; Paykel Health (FPH AU)</a> vs. <a href="https://www.smartkarma.com/entities/resmed-inc-cdi" target="_blank" data-smartkarma-citation="entities:22653:1" rel="noopener">ResMed (RMD AU)</a> price ratio has deviated more than two standard deviations from its one-year average, presenting a potential relative value opportunity.</li>
<li>
Highlights: Going long <a href="https://www.smartkarma.com/entities/resmed-inc-cdi" target="_blank" data-smartkarma-citation="entities:22653:1" rel="noopener">ResMed Inc (RMD AU)</a> and short <a href="https://www.smartkarma.com/entities/fisher-paykel-healthcare-cor" target="_blank" data-smartkarma-citation="entities:24208:1" rel="noopener">Fisher &amp; Paykel Health (FPH AU)</a> targets a 5% return.</li>
<li>
Why Read: Essential for quantitative traders seeking mean-reversion opportunities, with detailed execution framework, risk management protocols, and historical simulation showing the statistical basis for this relative value play.</li>
</ul>



Context: The Fisher &amp; Paykel Health (FPH AU) vs. ResMed (RMD AU) price ratio has deviated more than two standard deviations from its one-year average, presenting a potential relative value opportunity.

Highlights: Going long ResMed Inc (RMD AU) and short Fisher &amp; Paykel Health (FPH AU) targets a 5% return.

Why Read: Essential for quantitative traders seeking mean-reversion opportunities, with detailed execution framework, risk management protocols, and historical simulation showing the statistical basis for this relative value play.


ResMed (RMD AU)  Vs. Fisher & Paykel Healthcare (FPH AU): Aussie Statistical Arbitrage Reloaded

Financial News, Analysis and Data, FNArena

FNArena

Financial News, Analysis and Data

Online financial media company focused on Australian equities, with a global perspective

<ul><li>It was once feared weight-loss drugs would crush demand for sleep apnoea products.</li><li>ResMed&rsquo;s December quarter has shown very much the opposite is true.</li><li> ResMed&rsquo;s December quarter beats across most metrics US mask/device sales the standout GLP-1&rsquo;s support increasing demand, as foreshadowed by management Further double-digit earnings growth likely ahead</li></ul>

It was once feared weight-loss drugs would crush demand for sleep apnoea products.ResMed&rsquo;s December quarter has shown very much the opposite is true. ResMed&rsquo;s December quarter beats across most metrics US mask/device sales the standout GLP-1&rsquo;s support increasing demand, as foreshadowed by management Further double-digit earnings growth likely ahead

<ul><li>ResMed Inc. delivered a strong performance in the first quarter of fiscal year 2026, showcasing a robust operational and financial stance amidst challenging global market conditions.</li><li>The company reported a 9% growth in revenue, or 8% in constant currency, reflecting significant contributions across its product portfolio.</li><li>The U.S., Canada, and Latin American markets demonstrated high single-digit growth in device sales and double-digit growth in masks, contributing substantially to the overall revenue growth.</li></ul>

ResMed Inc. delivered a strong performance in the first quarter of fiscal year 2026, showcasing a robust operational and financial stance amidst challenging global market conditions.The company reported a 9% growth in revenue, or 8% in constant currency, reflecting significant contributions across its product portfolio.The U.S., Canada, and Latin American markets demonstrated high single-digit growth in device sales and double-digit growth in masks, contributing substantially to the overall revenue growth.

The Secret Behind ResMed’s Market Surge—AI, Awareness, & Smarter Sleep Campaigns!

<ul><li>ResMed's first-quarter result broadly met market expectations, though rising margins and potential for further capital management have been negated by US import tariff ambiguity.</li><li> ResMed updates with strong September quarter performance (but largely in line) Gross margin surprised, device revenues outperform expectation Uncertainty about US import tariff exemption weighs on share price Expects share buybacks of US$150m in each quarter of FY26 Ord Minnett sees scope for additional capital management initiatives</li></ul>

ResMed's first-quarter result broadly met market expectations, though rising margins and potential for further capital management have been negated by US import tariff ambiguity. ResMed updates with strong September quarter performance (but largely in line) Gross margin surprised, device revenues outperform expectation Uncertainty about US import tariff exemption weighs on share price Expects share buybacks of US$150m in each quarter of FY26 Ord Minnett sees scope for additional capital management initiatives

Tariff Uncertainty Negates ResMed's Q1 Positives

United States

ResMed Inc. develops, manufactures, and markets medical equipment for the treatment of sleep disordered breathing. The Company sells diagnostic and treatment devices in various countries through its subsidiaries and independent distributors.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

ResMed Inc (RMD AU)

ResMed’s Multi-Vector Growth Story: GLP-1 Tailwinds, Primary Care Expansion, and Digital Health!

ResMed's financial performance in the second quarter of fiscal year 2026 offers insights into its operational strengths and market challenges. The...

Baptista Research

ResMed (RMD AU) Vs. Fisher & Paykel Healthcare (FPH AU): Aussie Statistical Arbitrage Reloaded

Repeat pair trade with a 9% target-return in this proven pair amid significant deviation of the price ratio. Opportunity for quantitative traders...

Gaudenz Schneider

GLP-1s Drive Strong Quarter For ResMed

It was once feared weight-loss drugs would crush demand for sleep apnoea products. ResMed’s December quarter has shown very much the opposite is...

FNArena

The Secret Behind ResMed’s Market Surge—AI, Awareness, & Smarter Sleep Campaigns!

ResMed Inc. delivered a strong performance in the first quarter of fiscal year 2026, showcasing a robust operational and financial stance amidst...

Baptista Research

Tariff Uncertainty Negates ResMed's Q1 Positives

ResMed's first-quarter result broadly met market expectations, though rising margins and potential for further capital management have been...

FNArena

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)